Identification
- Name
- Hydrocortisone
- Accession Number
- DB00741 (APRD01019, DB07886)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. [PubChem]
- Structure
- Synonyms
- (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
- (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
- 11beta-hydrocortisone
- 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
- 11β-hydrocortisone
- 17-Hydroxycorticosterone
- 4-Pregnen-11beta,17alpha,21-triol-3,20-dione
- Cortisol
- Hidrocortisona
- Hydrocortisone
- Hydrocortisonum
- Kendall's compound F
- Reichstein's substance M
- External IDs
- NSC-10483
- Product Ingredients
Ingredient UNII CAS InChI Key Hydrocortisone aceponate 2340UP1L2G 74050-20-7 MFBMYAOAMQLLPK-FZNHGJLXSA-N Hydrocortisone acetate 3X7931PO74 50-03-3 ALEXXDVDDISNDU-JZYPGELDSA-N Hydrocortisone butyrate 05RMF7YPWN 13609-67-1 BMCQMVFGOVHVNG-TUFAYURCSA-N Hydrocortisone cypionate 4XDY25L70B 508-99-6 DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone phosphate 2Y87E22X71 3863-59-0 BGSOJVFOEQLVMH-VWUMJDOOSA-N Hydrocortisone probutate O6550D6K3A 72590-77-3 FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone sodium phosphate 0388G963HY 6000-74-4 RYJIRNNXCHOUTQ-OJJGEMKLSA-L Hydrocortisone sodium succinate 50LQB69S1Z 125-04-2 HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone valerate 68717P8FUZ 57524-89-7 FZCHYNWYXKICIO-FZNHGJLXSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End A-hydrocort Inj 1000mg/8ml Powder, for solution 1 g Intramuscular; Intravenous Hospira, Inc. 1993-12-31 2012-08-03 Canada A-hydrocort Inj 100mg/2ml Powder, for solution 100 mg Intramuscular; Intravenous Hospira, Inc. 1992-12-31 2012-08-03 Canada A-hydrocort Inj 250mg/2ml Powder, for solution 250 mg Intramuscular; Intravenous Hospira, Inc. 1992-12-31 2012-08-03 Canada A-hydrocort Inj 500mg/4ml Powder, for solution 500 mg Intramuscular; Intravenous Hospira, Inc. 1992-12-31 2012-08-03 Canada Alocort 1% - Crm Cream 1 % Topical Ucb Inc 1996-12-06 1998-04-21 Canada Aquacort Lotion 2.5% Lotion 2.5 % Topical Merit Industries Inc. 1992-12-31 2002-05-14 Canada Barriere HC 1% Cream; Jelly 1 % Topical Allen & Hanburys A Glaxo Canada Ltd. Co. 1979-12-31 1998-07-29 Canada Cortamed Ont 25 mg/g Ointment 2.5 % Ophthalmic Sandoz Canada Incorporated 1992-12-31 Not applicable Canada Cortate Crm 1% Cream 10 mg Topical Schering Plough 1980-12-31 2013-07-31 Canada Cortate Ont 1% Ointment 10 mg Topical Schering Plough 1980-12-31 2013-07-31 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End A-hydrocort Injection, powder, lyophilized, for solution 100 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2011-05-12 2017-08-04 US Ala Scalp Lotion 20 mg/mL Topical Crown Laboratories 1973-02-28 Not applicable US Alacort Cream 25 mg/g Topical Crown Laboratories 1973-03-09 Not applicable US Alacort Cream 10 mg/g Topical Crown Laboratories 1973-03-09 Not applicable US Anusol HC Cream 25 mg/g Topical Salix Pharmaceuticals 1984-06-06 Not applicable US Colocort Suspension 100 mg/60mL Rectal Paddock Laboratories, Inc. 1999-12-31 Not applicable US Euro-hydrocortisone Cream 2.5 % Topical Euro Pharm International Canada Inc Not applicable Not applicable Canada Home PapKit Cream 25 mg/g Topical International Brand Management, Llc 2016-09-15 Not applicable US Hydrocortisone Cream 25 mg/g Topical A S Medication Solutions 2006-03-31 Not applicable US Hydrocortisone Tablet 5 mg/1 Oral Kaiser Foundations Hospitals 2010-03-05 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 1% Hydrocortisone Cream 1 g/100g Topical Yuyao Jessie Commodity Co.,Ltd. 2015-12-01 Not applicable US 999 Itch Relieving Ointment 1 g/100g Topical Guangdong CR. Shunfeng Pharmaceutical Co Ltd 1989-07-20 Not applicable US 999 Itch Relieving Ointment 1 g/100g Topical Guangdong CR. Shunfeng Pharmaceutical Co Ltd 1989-07-20 Not applicable US Advanced Anti-itch Therapy Soap 1 g/100g Topical CVS Health 2016-06-10 Not applicable US Advanced Hydrocortisone Cream 10 mg/g Topical Ultra Seal Corporation 2011-04-05 Not applicable US Aftate Hydrocortisone Cream Cream 1 g/100g Topical Sabel Med Llc 2016-05-01 Not applicable US Ana Cool Rapid Soothing Cooling Formula Cream 10 mg/g Topical Ana Cool, Llc 2015-11-25 Not applicable US Anti Itch Lotion 1 g/100g Topical Walgreen 2012-03-27 Not applicable US Anti Itch Cream 1 g/100g Topical Rite Aid 2013-09-11 Not applicable US Anti Itch Cream 1 g/100g Topical Hyvee 2015-11-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acetasol HC Hydrocortisone (1.1 g/100mL) + Acetic acid (2.41 g/100mL) Solution Auricular (otic) Actavis Pharma Company 2002-09-10 Not applicable US Actinac Pwr Hydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg) Powder Topical Roussel Canada Inc. 1978-12-31 1996-09-09 Canada Actinac Pws Hydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg) Powder, for solution Topical Hoechst Roussel Canada Inc. 1994-12-31 2001-07-20 Canada Alocane Hydrocortisone acetate (5 mg/mL) + Lidocaine hydrochloride (945 mg/mL) Ointment Topical Product Quest 2014-11-11 Not applicable US Analpram HC Hydrocortisone acetate (25 mg/mL) + Pramoxine hydrochloride (10 mg/mL) Lotion Topical Ferndale Laboratories, Inc. 1996-01-01 2016-12-31 US Analpram HC Hydrocortisone acetate (10 mg/g) + Pramoxine hydrochloride (10 mg/g) Cream Topical Ferndale Laboratories, Inc. 1985-12-23 2016-09-30 US Analpram HC Hydrocortisone acetate (25 mg/mL) + Pramoxine hydrochloride (10 mg/mL) Lotion Topical Sebela Pharmaceuticals Inc. 1996-01-01 Not applicable US Analpram HC Hydrocortisone acetate (10 mg/g) + Pramoxine hydrochloride (10 mg/g) Cream Topical Sebela Pharmaceuticals Inc. 1985-12-23 Not applicable US Anodan-HC 10mg Suppositories Hydrocortisone acetate (10 mg) + Zinc sulfate (10 mg) Suppository Rectal Odan Laboratories Ltd 1998-08-13 Not applicable Canada Anodan-HC Ointment Hydrocortisone acetate (0.5 %) + Zinc sulfate (0.5 %) Ointment Rectal; Topical Odan Laboratories Ltd 1995-12-31 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acella Hydrocortisone Acetate - Pramoxine Singles Hydrocortisone acetate (2.5 g/100g) + Pramocaine (1 g/100g) Cream Topical Acella Pharmaceuticals, LLC 2010-11-08 2017-08-17 US Ala Quin Hydrocortisone (5 mg/g) + Clioquinol (30 mg/g) Cream Topical Crown Laboratories 1970-08-19 Not applicable US Alcortin Hydrocortisone (2 g/100g) + Diiodohydroxyquinoline (1 g/100g) Gel Topical Primus Pharmaceuticals 2003-07-25 Not applicable US Alcortin A Hydrocortisone acetate (20 mg/g) + Aloe Polysaccharide (10 mg/g) + Diiodohydroxyquinoline (10 mg/g) Gel Topical Novum Pharma, Llc 2015-03-01 Not applicable US Ana-Lex Hydrocortisone acetate (20 mg/g) + Lidocaine hydrochloride (20 mg/g) Cream Topical Avion Pharmaceuticals, Llc 2008-02-28 Not applicable US Analpram Advanced Hydrocortisone acetate + Pramoxine hydrochloride Kit Sebela Pharmaceuticals Inc. 2010-10-01 2017-02-28 US Analpram Advanced Hydrocortisone acetate + Pramoxine hydrochloride Kit Ferndale Laboratories, Inc. 2010-10-01 2016-12-31 US Analpram Advanced Hydrocortisone acetate + Pramoxine hydrochloride Kit Oral Sebela Pharmaceuticals Inc. 2010-10-01 2017-02-23 US Analpram Advanced Hydrocortisone acetate + Pramoxine hydrochloride Kit Ferndale Laboratories, Inc. 2010-10-01 2016-04-30 US Analpram Advanced Hydrocortisone acetate + Pramoxine hydrochloride Kit Sebela Pharmaceuticals Inc. 2010-08-01 2017-02-28 US - International/Other Brands
- Acticort / Aeroseb HC / Ala-Scalp / Algicirtis / Aquanil HC / Beta-HC / Cetacort / Cortaid / Delacort / Ficortril / Genacort / Glycort / Komed HC / Lacticare HC / Lubricort / Medicort / Meusicort / Micort-HC / Mildison / Nogenic HC / Nutracort / Nystaform-HC / Otocort / Penecort / Permicort / Polcort H / Preparation H Hydrocortisone Cream / Prepcort / Prevex HC / Proctocort / Proctocream / Protocort / Remederm HC / Sanatison / Scalpicin Capilar / Schericur / Sigmacort / Synacort / Systral Hydrocort / Timocort
- Categories
- 11-Hydroxycorticosteroids
- 17-Hydroxycorticosteroids
- Administration, Topical
- Adrenal Cortex Hormones
- Adrenals
- Aerosols
- Anti-Inflammatory Agents
- BCRP/ABCG2 Inhibitors
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inducers (weak)
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hydroxycorticosteroids
- Hyperglycemia-Associated Agents
- Immunosuppressive Agents
- Nasal Preparations
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Pregnanes
- Pregnenediones
- Pregnenes
- Steroids
- UNII
- WI4X0X7BPJ
- CAS number
- 50-23-7
- Weight
- Average: 362.4599
Monoisotopic: 362.20932407 - Chemical Formula
- C21H30O5
- InChI Key
- JYGXADMDTFJGBT-VWUMJDOOSA-N
- InChI
- InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
- IUPAC Name
- (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
- SMILES
- [H][[email protected]@]12CC[[email protected]](O)(C(=O)CO)[[email protected]@]1(C)C[[email protected]](O)[[email protected]@]1([H])[[email protected]@]2([H])CCC2=CC(=O)CC[[email protected]]12C
Pharmacology
- Indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
- Structured Indications
- Acute Gouty Arthritis
- Allergic Rhinitis (AR)
- Allergic corneal marginal ulcers
- Ankylosing Spondylitis (AS)
- Anterior Segment Inflammation
- Aspiration Pneumonitis
- Asthma Bronchial
- Atopic Dermatitis (AD)
- Berylliosis
- Bullous dermatitis herpetiformis
- Congenital Adrenal Hyperplasia (CAH)
- Conjunctivitis, Seasonal Allergic
- Corneal Inflammation
- Crohn's Disease (CD)
- Dermatitis, Contact
- Dermatomyositis
- Dermatosis
- Drug hypersensitivity reaction
- Epicondylitis
- Erythroblastopenia
- Hypercalcemia of Malignancy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Iridocyclitis
- Iritis
- Leukaemia, Acute
- Leukemias
- Loeffler's syndrome
- Malignant Lymphomas
- Mycosis Fungoides (MF)
- Ophthalmia, Sympathetic
- Optic Neuritis
- Pemphigus
- Primary adrenocortical insufficiency
- Proteinuria
- Psoriatic Arthritis
- Rheumatic heart disease, unspecified
- Rheumatoid Arthritis
- Rheumatoid Arthritis, Juvenile
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Serum Sickness
- Severe Seborrheic Dermatitis
- Stevens Johnson Syndrome
- Synovitis
- Systemic Lupus Erythematosus (SLE)
- Trichinosis
- Tuberculous Meningitis
- Ulcerative Colitis (UC)
- Acquired immune hemolytic anemia
- Acute Bursitis
- Acute Tenosynovitis
- Diffuse posterior uveitis
- Disseminated Pulmonary Tuberculosis
- Exfoliative erythroderma
- Fulminating Pulmonary Tuberculosis
- Non-suppurative Thyroiditis
- Severe Psoriasis
- Subacute Bursitis
- Symptomatic Sarcoidosis
- Systemic Dermatomyositis
- Varicella-zoster virus acute retinal necrosis
- Pharmacodynamics
Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
- Mechanism of action
Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Target Actions Organism AGlucocorticoid receptor agonistHuman AAnnexin A1 agonistHuman UCorticosteroid 11-beta-dehydrogenase isozyme 2 Not Available Human U3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 Not Available Human - Absorption
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
- Volume of distribution
- Not Available
- Protein binding
95%
- Metabolism
Primarily hepatic via CYP3A4
- Route of elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
- Half life
6-8 hours
- Clearance
- Not Available
- Toxicity
Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Hydrocortisone. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline. Experimental 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrocortisone. Investigational Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Hydrocortisone. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Hydrocortisone. Approved, Experimental, Investigational Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone. Approved, Investigational, Withdrawn Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Hydrocortisone. Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Hydrocortisone. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone. Experimental, Investigational Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Hydrocortisone. Approved, Withdrawn Aldesleukin Hydrocortisone may decrease the antineoplastic activities of Aldesleukin. Approved Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Hydrocortisone. Investigational Almasilate The bioavailability of Hydrocortisone can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Hydrocortisone. Experimental Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone. Approved Aloglutamol The bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone. Experimental Aluminium The bioavailability of Hydrocortisone can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of Hydrocortisone can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Hydrocortisone can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone. Approved Amiodarone The metabolism of Hydrocortisone can be decreased when combined with Amiodarone. Approved, Investigational Amphotericin B Hydrocortisone may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Hydrocortisone. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Hydrocortisone. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone. Approved, Investigational Apalutamide The serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Hydrocortisone. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Hydrocortisone. Approved, Investigational Aprepitant The serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone. Approved, Investigational Asunaprevir The serum concentration of Asunaprevir can be decreased when it is combined with Hydrocortisone. Approved, Investigational, Withdrawn Atazanavir The metabolism of Hydrocortisone can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Hydrocortisone can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin. Approved Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocortisone. Approved Azosemide Hydrocortisone may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrocortisone. Investigational Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with BCG vaccine. Investigational Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrocortisone. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Hydrocortisone. Experimental Bendroflumethiazide Hydrocortisone may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Hydrocortisone. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Hydrocortisone. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone. Approved, Investigational Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Hydrocortisone. Experimental Bismuth Subcitrate The bioavailability of Hydrocortisone can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate. Approved, Experimental Boceprevir The metabolism of Hydrocortisone can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Hydrocortisone can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone. Approved, Investigational Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Hydrocortisone. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrocortisone. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Hydrocortisone. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Hydrocortisone. Approved, Experimental Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Hydrocortisone. Investigational, Withdrawn Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Hydrocortisone. Experimental Bumetanide Hydrocortisone may increase the hypokalemic activities of Bumetanide. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Hydrocortisone. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone. Approved, Nutraceutical Calcium Carbonate The bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate. Experimental Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone. Approved Capromab pendetide Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone. Experimental, Investigational Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrocortisone. Experimental Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Hydrocortisone. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Hydrocortisone. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Hydrocortisone. Approved, Investigational Ceritinib The serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Hydrocortisone. Approved, Withdrawn Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Hydrocortisone. Approved, Investigational, Vet Approved Chlorothiazide Hydrocortisone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Hydrocortisone can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Chlorthalidone Hydrocortisone may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone. Approved Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone. Experimental Cinoxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cinoxacin. Approved, Investigational, Withdrawn Clarithromycin The metabolism of Hydrocortisone can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Hydrocortisone can be decreased when combined with Clemastine. Approved, Investigational Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Hydrocortisone. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Clotrimazole The metabolism of Hydrocortisone can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Hydrocortisone can be decreased when combined with Cobicistat. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Hydrocortisone. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone. Approved, Investigational Conjugated estrogens The serum concentration of Hydrocortisone can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Coumaphos. Vet Approved Crizotinib The metabolism of Hydrocortisone can be decreased when combined with Crizotinib. Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Hydrocortisone. Approved, Investigational Cyclopenthiazide Hydrocortisone may increase the hypokalemic activities of Cyclopenthiazide. Experimental Cyclosporine The metabolism of Hydrocortisone can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone. Approved Dabrafenib The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib. Approved, Investigational Daidzein The serum concentration of Hydrocortisone can be increased when it is combined with Daidzein. Experimental Danazol Hydrocortisone may increase the fluid retaining activities of Danazol. Approved Darunavir The metabolism of Hydrocortisone can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib. Approved, Investigational Decamethonium The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decamethonium. Approved Deferasirox The serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Hydrocortisone can be decreased when combined with Delavirdine. Approved Demecarium The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Demecarium. Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydrocortisone. Investigational Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Hydrocortisone. Approved, Vet Approved Dienestrol The serum concentration of Hydrocortisone can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Hydrocortisone. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone. Approved, Investigational Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydrocortisone. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydrocortisone. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Hydrocortisone. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydrocortisone. Approved, Investigational Diltiazem The metabolism of Hydrocortisone can be decreased when combined with Diltiazem. Approved, Investigational Distigmine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Donepezil. Approved Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone. Approved, Investigational Doxycycline The metabolism of Hydrocortisone can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Hydrocortisone can be decreased when combined with Dronedarone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Hydrocortisone. Withdrawn Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Hydrocortisone. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Hydrocortisone. Investigational Echothiophate The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone. Approved Edrophonium The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Edrophonium. Approved Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone. Approved Enoxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Hydrocortisone can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Hydrocortisone. Approved Epitizide Hydrocortisone may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of Hydrocortisone can be increased when it is combined with Equol. Investigational Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Hydrocortisone. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Hydrocortisone. Approved Erythromycin The metabolism of Hydrocortisone can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Estradiol The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Hydrocortisone can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Hydrocortisone can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Hydrocortisone can be increased when it is combined with Estrone. Approved Etacrynic acid Hydrocortisone may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Hydrocortisone. Experimental Ethinyl Estradiol The serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Hydrocortisone. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Hydrocortisone. Approved, Investigational Everolimus The serum concentration of Everolimus can be increased when it is combined with Hydrocortisone. Approved Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Hydrocortisone. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Hydrocortisone. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Hydrocortisone. Approved Fenthion The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Hydrocortisone. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Hydrocortisone. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Hydrocortisone. Experimental Fingolimod Hydrocortisone may increase the immunosuppressive activities of Fingolimod. Approved, Investigational Fleroxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Hydrocortisone. Approved, Withdrawn Fluconazole The metabolism of Hydrocortisone can be decreased when combined with Fluconazole. Approved, Investigational Flumequine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Hydrocortisone. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Hydrocortisone. Experimental Fluoxymesterone Hydrocortisone may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Hydrocortisone. Approved, Investigational Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Hydrocortisone. Approved Fluvoxamine The metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide Hydrocortisone may increase the hypokalemic activities of Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid. Approved, Investigational G17DT The risk or severity of adverse effects can be increased when Hydrocortisone is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Hydrocortisone can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Hydrocortisone is combined with GI-5005. Investigational Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone. Approved, Investigational GLPG-0492 Hydrocortisone may increase the fluid retaining activities of GLPG-0492. Investigational Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrocortisone. Approved Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Hydrocortisone. Experimental Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrocortisone. Investigational Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Hydrocortisone. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of Hydrocortisone can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Hydrocortisone. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone. Approved, Investigational Hydrochlorothiazide Hydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Hydrocortisone may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone. Approved Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Hydrocortisone. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone. Approved, Investigational Idelalisib The metabolism of Hydrocortisone can be decreased when combined with Idelalisib. Approved Imatinib The metabolism of Hydrocortisone can be decreased when combined with Imatinib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Hydrocortisone. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Hydrocortisone. Approved Indapamide Hydrocortisone may increase the hypokalemic activities of Indapamide. Approved Indinavir The metabolism of Hydrocortisone can be decreased when combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Hydrocortisone. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Hydrocortisone. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 225. Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone. Approved Ipidacrine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ipidacrine. Experimental Isavuconazole The serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Hydrocortisone can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurophate The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Hydrocortisone. Withdrawn Isradipine The metabolism of Hydrocortisone can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Hydrocortisone can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Hydrocortisone can be increased when it is combined with Ivacaftor. Approved Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Hydrocortisone. Experimental Ketoconazole The metabolism of Hydrocortisone can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Hydrocortisone. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Hydrocortisone. Approved Leflunomide The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Leflunomide. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin. Approved, Investigational Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrocortisone. Approved Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone. Approved Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Hydrocortisone. Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Hydrocortisone. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Hydrocortisone. Experimental Lopinavir The metabolism of Hydrocortisone can be decreased when combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone. Approved, Investigational Lorpiprazole The serum concentration of Hydrocortisone can be increased when it is combined with Lorpiprazole. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Hydrocortisone. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Hydrocortisone. Approved, Investigational Luliconazole The serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Hydrocortisone. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Hydrocortisone. Illicit, Investigational, Withdrawn Magaldrate The bioavailability of Hydrocortisone can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium hydroxide The bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Hydrocortisone can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone. Approved Magnesium silicate The bioavailability of Hydrocortisone can be decreased when combined with Magnesium silicate. Approved, Experimental Magnesium Trisilicate The bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Hydrocortisone. Approved Mefloquine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone. Approved Mesterolone Hydrocortisone may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Hydrocortisone can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Hydrocortisone. Experimental Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone. Approved Methallenestril The serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Hydrocortisone may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone. Approved, Vet Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone. Approved Methyltestosterone Hydrocortisone may increase the fluid retaining activities of Methyltestosterone. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Hydrocortisone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Metoclopramide. Approved, Investigational Metolazone Hydrocortisone may increase the hypokalemic activities of Metolazone. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Hydrocortisone. Experimental Mifepristone The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrocortisone. Approved Minaprine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Mitotane The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Hydrocortisone. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Hydrocortisone. Experimental Moxestrol The serum concentration of Hydrocortisone can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Hydrocortisone. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nalidixic Acid. Approved, Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Hydrocortisone. Approved Nandrolone Hydrocortisone may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate Hydrocortisone may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Hydrocortisone. Approved, Vet Approved Natalizumab The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab. Approved, Investigational Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Nefazodone The metabolism of Hydrocortisone can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Hydrocortisone. Approved, Investigational Netupitant The serum concentration of Hydrocortisone can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Hydrocortisone. Approved, Investigational Nicorandil The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Hydrocortisone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone. Approved Nilotinib The metabolism of Hydrocortisone can be decreased when combined with Nilotinib. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone. Approved, Investigational, Withdrawn Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Hydrocortisone. Approved Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Norfloxacin. Approved Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Hydrocortisone. Approved, Investigational Olaparib The metabolism of Hydrocortisone can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Hydrocortisone. Vet Approved Osimertinib The serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib. Approved Oxandrolone Hydrocortisone may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Oxolinic acid. Experimental Oxymetholone Hydrocortisone may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone. Approved, Withdrawn Palbociclib The serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib. Approved, Investigational Paraoxon The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Hydrocortisone. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Hydrocortisone. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone. Approved Pazufloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Hydrocortisone. Approved, Investigational, Vet Approved, Withdrawn Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone. Approved, Investigational, Withdrawn Phenobarbital The serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone. Approved, Investigational Phenytoin The serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone. Approved, Investigational Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pipemidic acid. Experimental Piretanide Hydrocortisone may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Hydrocortisone. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Hydrocortisone. Approved Pitolisant The serum concentration of Hydrocortisone can be decreased when it is combined with Pitolisant. Approved, Investigational Polyestradiol phosphate The serum concentration of Hydrocortisone can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Hydrocortisone may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The metabolism of Hydrocortisone can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Hydrocortisone. Experimental, Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone. Approved Primidone The serum concentration of Hydrocortisone can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Hydrocortisone. Experimental Promestriene The serum concentration of Hydrocortisone can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Hydrocortisone. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Hydrocortisone. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Hydrocortisone. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Hydrocortisone. Approved Prulifloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Hydrocortisone. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of Hydrocortisone can be increased when it is combined with Quinestrol. Approved Quinethazone Hydrocortisone may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Hydrocortisone. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Hydrocortisone. Withdrawn Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone. Approved, Experimental, Investigational Rifabutin The serum concentration of Hydrocortisone can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Hydrocortisone. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone. Approved Rindopepimut The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Hydrocortisone. Approved, Investigational, Withdrawn Roflumilast Roflumilast may increase the immunosuppressive activities of Hydrocortisone. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone. Approved, Investigational Rosoxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Hydrocortisone. Approved Rotavirus Vaccine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rubella virus vaccine. Approved, Investigational Rucaparib The metabolism of Hydrocortisone can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Hydrocortisone. Approved Saquinavir The metabolism of Hydrocortisone can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone. Approved Secoisolariciresinol The serum concentration of Hydrocortisone can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Hydrocortisone. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Hydrocortisone. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Hydrocortisone. Investigational Sildenafil The metabolism of Hydrocortisone can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Hydrocortisone. Approved Siltuximab The serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Hydrocortisone. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone. Approved, Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sitafloxacin. Experimental, Investigational Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone. Approved, Investigational Sodium bicarbonate The bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate. Approved Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrocortisone. Investigational Sparfloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Hydrocortisone is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Hydrocortisone. Investigational St. John's Wort The serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Hydrocortisone may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol Hydrocortisone may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Hydrocortisone can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone. Approved Sulfisoxazole The metabolism of Hydrocortisone can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Hydrocortisone. Approved, Investigational Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Hydrocortisone. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine. Investigational, Withdrawn Tacrolimus Tacrolimus may increase the immunosuppressive activities of Hydrocortisone. Approved, Investigational Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Hydrocortisone. Investigational Tecemotide The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Hydrocortisone. Approved, Withdrawn Telithromycin The metabolism of Hydrocortisone can be decreased when combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Hydrocortisone. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Hydrocortisone. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Hydrocortisone. Vet Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Hydrocortisone. Experimental Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone. Approved Testosterone Hydrocortisone may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate Hydrocortisone may increase the fluid retaining activities of Testosterone cypionate. Approved Testosterone enanthate Hydrocortisone may increase the fluid retaining activities of Testosterone enanthate. Approved Testosterone propionate Hydrocortisone may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate Hydrocortisone may increase the fluid retaining activities of Testosterone undecanoate. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Hydrocortisone is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Hydrocortisone. Approved Tibolone The serum concentration of Hydrocortisone can be increased when it is combined with Tibolone. Approved, Investigational Ticlopidine The metabolism of Hydrocortisone can be decreased when combined with Ticlopidine. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Hydrocortisone. Investigational Tocilizumab The serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab. Approved Tofacitinib Hydrocortisone may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Hydrocortisone. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Hydrocortisone. Approved, Investigational Torasemide Hydrocortisone may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone. Approved, Investigational Trastuzumab Trastuzumab may increase the neutropenic activities of Hydrocortisone. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Hydrocortisone. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trichlorfon. Vet Approved Trichlormethiazide Hydrocortisone may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone. Investigational Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone. Investigational, Withdrawn Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone. Approved Tromethamine The bioavailability of Hydrocortisone can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Vemurafenib The serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Hydrocortisone can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Hydrocortisone can be decreased when combined with Verapamil. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone. Approved, Investigational Vincristine The excretion of Vincristine can be decreased when combined with Hydrocortisone. Approved, Investigational Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrocortisone. Approved, Investigational Voriconazole The metabolism of Hydrocortisone can be decreased when combined with Voriconazole. Approved, Investigational Warfarin Hydrocortisone may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Hydrocortisone. Approved, Investigational Zeranol The serum concentration of Hydrocortisone can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Hydrocortisone. Approved, Investigational, Withdrawn Ziprasidone The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone. Withdrawn - Food Interactions
- Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.
References
- Synthesis Reference
Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, "Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof." U.S. Patent US4264584, issued March, 1974.
US4264584- General References
- de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. [PubMed:12932892]
- Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. [PubMed:6461917]
- KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. [PubMed:13233328]
- External Links
- Human Metabolome Database
- HMDB0014879
- KEGG Drug
- D00088
- KEGG Compound
- C00735
- PubChem Compound
- 5754
- PubChem Substance
- 46505089
- ChemSpider
- 5551
- BindingDB
- 13775
- ChEBI
- 17650
- ChEMBL
- CHEMBL389621
- Therapeutic Targets Database
- DAP000718
- PharmGKB
- PA449905
- IUPHAR
- 2868
- Guide to Pharmacology
- GtP Drug Page
- HET
- HCY
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Hydrocortisone
- ATC Codes
- S02BA01 — HydrocortisoneS01CA03 — Hydrocortisone and antiinfectives
- S01CA — Corticosteroids and antiinfectives in combination
- S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- S01CB — Corticosteroids/antiinfectives/mydriatics in combination
- S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- S03CA — Corticosteroids and antiinfectives in combination
- S03C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
- S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
- S — SENSORY ORGANS
- S02CA — Corticosteroids and antiinfectives in combination
- S02C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
- S02 — OTOLOGICALS
- S — SENSORY ORGANS
- D07AB — Corticosteroids, moderately potent (group II)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D07AA — Corticosteroids, weak (group I)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D07BB — Corticosteroids, moderately potent, combinations with antiseptics
- D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- C05AA — Corticosteroids
- C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
- C05 — VASOPROTECTIVES
- C — CARDIOVASCULAR SYSTEM
- D07AC — Corticosteroids, potent (group III)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D07BA — Corticosteroids, weak, combinations with antiseptics
- D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- S01BA — Corticosteroids, plain
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- D07CA — Corticosteroids, weak, combinations with antibiotics
- D07C — CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- A01AC — Corticosteroids for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- S01BB — Corticosteroids and mydriatics in combination
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- H02AB — Glucocorticoids
- H02A — CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
- H02 — CORTICOSTEROIDS FOR SYSTEMIC USE
- H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
- D07XA — Corticosteroids, weak, other combinations
- D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- A07EA — Corticosteroids acting locally
- A07E — INTESTINAL ANTIINFLAMMATORY AGENTS
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 68:04.00 — Adrenals
- 84:06.00 — Anti-inflammatory Agents
- 56:36.00 — Anti-inflammatory Agents
- PDB Entries
- 2v95 / 2vdy / 4c49 / 4p6x / 5hgc
- FDA label
- Download (30 KB)
- MSDS
- Download (73.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Hi tech pharmacal co inc
- Allergan herbert div allergan inc
- Del ray laboratories inc
- Salix pharmaceuticals inc
- Bayer pharmaceuticals corp
- Monarch pharmaceuticals inc
- Valeant pharmaceuticals international
- Westwood squibb pharmaceuticals inc
- C and m pharmacal inc
- Pharmaceutical assoc inc div beach products
- Actavis mid atlantic llc
- Alpharma us pharmaceuticals division
- Altana inc
- Ambix laboratories div organics corp america
- Everylife
- E fougera div altana inc
- G and w laboratories inc
- Ingram pharmaceutical co
- Ivax pharmaceuticals inc
- Naska pharmacal co inc div rugby darby group cosmetics
- Perrigo new york inc
- Pharmaderm div altana inc
- Pharmafair inc
- Stiefel laboratories inc
- Syosset laboratories inc
- Taro pharmaceuticals usa inc
- Teva pharmaceuticals usa inc
- Topiderm inc
- Usl pharma inc
- Vintage pharmaceuticals inc
- Whiteworth towne paulsen inc
- Sanofi aventis us llc
- Coria laboratories ltd
- Medicis pharmaceutical corp
- Paddock laboratories inc
- Ani pharmaceuticals inc
- Teva pharmaceuticals usa
- Healthpoint ltd
- Allergan herbert skin care div allergan inc
- Pharmacia and upjohn co
- Baker norton pharmaceuticals inc
- Solvay pharmaceuticals
- Beta dermaceuticals inc
- Bluline laboratories inc
- Heran pharmaceutical inc
- Mericon industries inc
- Perrigo co
- Pfizer global research development
- Carolina medical products co
- Dermik laboratories div aventis pharmaceuticals inc
- Torch laboratories inc
- X gen pharmaceuticals inc
- Jsj pharmaceuticals llc
- Pfizer laboratories div pfizer inc
- Barr laboratories inc
- Elkins sinn div ah robins co inc
- John j ferrante
- Impax laboratories inc
- Inwood laboratories inc sub forest laboratories inc
- Lannett co inc
- Nexgen pharma inc
- Panray corp sub ormont drug and chemical co inc
- Parke davis div warner lambert co
- Purepac pharmaceutical co
- Roxane laboratories inc
- Sandoz inc
- Stiefel a gsk co
- Vintage pharmaceuticals llc
- Watson laboratories inc
- West ward pharmaceutical corp
- Merck and co inc
- Pfipharmecs div pfizer inc
- Schwarz pharma inc
- Able laboratories inc
- Hr cenci laboratories inc
- Ferndale laboratories inc
- Akorn inc
- Bel mar laboratories inc
- Colgate oral pharmaceuticals inc
- Taro pharmaceutical industries ltd
- Triax pharmaceuticals llc
- Yamanouchi europe bv
- Savage laboratories inc div altana inc
- Abbott laboratories pharmaceutical products div
- Abbott laboratories hosp products div
- Hospira inc
- Abraxis pharmaceutical products
- Baxter healthcare corp anesthesia and critical care
- International medication systems ltd
- Taro pharmaceuticals inc
- Ranbaxy laboratories inc
- Packagers
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- AG Marin Pharmaceuticals
- Alaven Pharmaceutical
- Alcon Laboratories
- Amerisource Health Services Corp.
- Ani Pharmaceuticals
- Anip Acquisition Co.
- Arbor Pharmaceuticals Incorporated
- A-S Medication Solutions LLC
- Avidas Pharmaceuticals
- Bay Pharma Inc.
- Bayer Healthcare
- Bergen Brunswig
- Beta Dermaceuticals
- Bio Pharm Inc.
- Bristol-Myers Squibb Co.
- C.O. Truxton Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Carolina Medical Products Co.
- Chattem Chemicals Inc.
- Co Med Pharmaceuticals Inc.
- Colgate Oral
- Combe Inc.
- Consolidated Midland Corp.
- Contract Pharm
- Crown Laboratories Inc.
- Cutis Pharma Inc.
- Cypress Pharmaceutical Inc.
- Darby Dental Supply Co. Inc.
- Del Ray Dermatology
- Dermik Labs
- DispenseXpress Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Dofs Laboratories
- DPT Laboratories Ltd.
- DSC Laboratories
- E. Fougera and Co.
- ECR Pharmaceuticals
- Elkins-Sinn Inc.
- Enterprises Importfab Inc.
- Ferndale Labs
- G & W Labs
- Genesis Pharmaceutical Inc.
- Gertz
- H and H Laboratories
- H.J. Harkins Co. Inc.
- Harmony Laboratories Inc.
- Hi Tech Pharmacal Co. Inc.
- Hospira Inc.
- Inyx Usa Ltd.
- JHP Pharmaceuticals LLC
- Johnson & Johnson Healthcare
- JSJ Pharmaceuticals Inc.
- Kaiser Foundation Hospital
- Keltman Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Lehigh Valley Technologies Inc.
- Lyne Laboratories Inc.
- Major Pharmaceuticals
- Mallinckrodt Inc.
- Martin Surgical Supply
- Meda AB
- Mikart Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- National Vitamin Company
- Nexgen Pharma Inc.
- Nycomed Inc.
- Paddock Labs
- Palmetto Pharmaceuticals Inc.
- Patheon Inc.
- Perrigo Co.
- Person & Covey
- Pfizer Inc.
- Pharmacia Inc.
- Pharmaderm
- Pharmedix
- Physician Partners Ltd.
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Professional Co.
- Prometic Pharma Inc.
- Qualitest
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Redpharm Drug
- Resource Optimization and Innovation LLC
- Rising Pharmaceuticals
- River's Edge Pharmaceuticals
- Rouses Point Pharmaceuticals LLC
- Salix Pharmaceuticals
- Sandhills Packaging Inc.
- Sandoz
- Sanofi-Aventis Inc.
- Schwarz Pharma Inc.
- Solvay Pharmaceuticals
- Southwood Pharmaceuticals
- Stanley Pharmaceuticals Ltd.
- Stat Rx Usa
- Stat Scripts LLC
- Summers Labs
- Suppositoria Laboratories Inc.
- Taro Pharmaceuticals USA
- Teva Pharmaceutical Industries Ltd.
- Topiderm Inc.
- Triax Pharmaceuticals LLC
- UCB Pharma
- United Pharmaceuticals
- United Research Laboratories Inc.
- Universal Laboratories Inc.
- Upsher Smith Laboratories
- Veratex Corp.
- Vertical Pharmaceuticals Inc.
- Vintage Pharmaceuticals Inc.
- West-Ward Pharmaceuticals
- Wockhardt Ltd.
- WraSer Pharmaceuticals
- Wyeth Pharmaceuticals
- Dosage forms
Form Route Strength Injection, powder, lyophilized, for solution Intramuscular; Intravenous 100 mg/2mL Powder Topical Powder, for solution Topical Soap Topical 1 g/100g Lotion Topical 20 mg/mL Cream Topical 1 % Kit Suppository Rectal Ointment Rectal; Topical Cream Topical 5 mg/g Solution Topical 1 g/100g Ointment Topical 1.02 g/100g Cream; jelly Topical 1 % Lotion Topical .088 mL/88mL Cream Topical .01 g/g Cream Topical 1 g/g Cream Topical 10 mg/g Suspension Auricular (otic) Spray Topical 1 g/100g Cream Topical 0.5 % Spray Topical 10 g/mL Ointment Ophthalmic 2.5 % Ointment Topical 10 mg Tablet Oral 10 mg Tablet Oral 20 mg Enema Rectal 100 mg Enema; suspension Rectal 100 mg Ointment Topical 100 g/g Cream Topical 1 mg Aerosol, foam Rectal 10 % Aerosol, foam Rectal 1500 mg/15g Aerosol, foam Topical 1500 mg/15g Suppository Rectal 10 mg Suppository Rectal 40 mg Suspension Topical Ointment Topical 10 mg/g Gel Topical 10 mg/g Liquid Topical 10 mg/mL Lotion Topical 1 g/100g Lotion Topical 10 mg/g Gel Topical 1 mg/g Lotion Topical 1 mg/mL Lotion Topical 1.18 mL/118mL Kit Topical Lotion Topical .75 g/100mL Cream Topical .284 g/28.4g Cream Topical .284 g/287.4g Cream Topical 1 g/100mL Cream Topical 2.5 % Solution Topical 2.5 % Kit Oral Ointment Topical 10 mg/mL Ointment Topical 1 mL/100mL Lotion Topical 1 g/mL Cream Topical .5 g/100g Suppository Rectal .025 g/2g Suppository Rectal 25 mg/2g Lotion / shampoo Topical 5 mg/mL Shampoo Topical 5 mg/mL Aerosol, spray Topical 1.13 g/113g Cream Topical 1 h/100g Cream Topical 10 mg/mL Cream Topical 25 mg/g Enema Rectal 100 mg/60mL Gel Topical 1 g/100g Lotion Topical 25 mg/mL Ointment Topical 25 mg/1 Ointment Topical 25 mg/g Ointment Topical 5 mg/g Shampoo Topical 1 g/100mL Suspension Rectal 100 mg/60mL Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral 5 mg/1 Ointment Topical 1.12 g/100g Suppository Rectal 25 mg/1 Suppository Rectal 30 mg/1 Solution Auricular (otic) Cream Topical 1 mg/g Ointment Topical 1 mg/g Solution Topical 1 mg/mL Cream Topical 500 mg Cream Topical 1 g Cream Topical 1.02 g/100g Cream Topical 5 mg Cream Topical 10 mg Ointment Topical 0.5 % Ointment Topical 1 % Powder, for solution Intramuscular; Intravenous 100 mg Powder, for solution Intramuscular; Intravenous 250 mg Powder, for solution Intramuscular; Intravenous 500 mg Powder, for solution Intramuscular; Intravenous 1 g Cream Topical 140 mg/14g Cream Topical 2 mg/g Ointment Topical 2 mg/g Lotion Topical 1 g/100mL Cream Topical 0.2 % Ointment Topical 0.2 % Lotion Topical 1 g/88mL Cream Topical 1 g/100g Ointment Topical 1 g/100g Cream Topical .5 % Cream Rectal Cream Rectal; Topical Gel Rectal Liquid Topical 5 mg/mL Liquid Topical 9 mg/mL Spray Topical 10 mg/mL Cream Topical .009 g/1 Suspension Auricular (otic); Ophthalmic Solution / drops Auricular (otic) Suspension / drops Auricular (otic) Ointment Ophthalmic Suspension Ophthalmic Lotion Topical 5 mg/g Lotion Topical 20 mg/g Kit Lipstick Topical .005 g/g Lotion Topical .025 mg/2.5mL Gel Topical Cream Topical 7.5 g/100mL Lotion Topical Ointment Topical Cream Topical Liquid Topical .28 mg/100mL Aerosol Rectal Aerosol, foam Topical Ointment Rectal Ointment Rectal; Topical 750 mg Cream Topical .51 g/100g Cream Topical 1 mg/100mL Lotion Topical 2.5 % Liquid Topical 10 mg/g Liquid Topical Liquid Topical 1 g/100mL Injection, powder, for solution Intramuscular; Intravascular 100 mg/2mL Injection, powder, for solution Intramuscular; Intravenous 100 mg/2mL Injection, powder, for solution Intramuscular; Intravenous 1000 mg/8mL Injection, powder, for solution Intramuscular; Intravenous 250 mg/2mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/4mL Lotion Topical 1 mL/100mL Ointment Auricular (otic); Ophthalmic Solution / drops Ophthalmic Solution Topical 25 mg/mL Lotion Topical 1 % Cream Topical 2 % Cream Topical 280 mg/28g Cream Topical 1.12 g/100g Cream Topical 10 mg/L Spray Topical 10 g/L - Prices
Unit description Cost Unit Locoid Lipocream 0.1% Cream 60 gm Tube 335.36USD tube Cortifoam 90 mg Foam 15 gm Can 239.99USD can Locoid 0.1% Solution 60ml Bottle 233.15USD bottle Locoid Lipocream 0.1% Cream 45 gm Tube 200.98USD tube Locoid 0.1% Cream 45 gm Tube 183.83USD tube Locoid 0.1% Ointment 45 gm Tube 174.86USD tube Pandel 0.1% Cream 45 gm Tube 161.37USD tube Pandel 0.1% Cream 15 gm Tube 138.56USD tube Proctocort 1% Cream 28.35 gm Tube 127.51USD tube Anusol-HC 2.5% Cream 30 gm Tube 106.45USD tube Locoid Lipocream 0.1% Cream 15 gm Tube 85.41USD tube Texacort 2.5% Solution 30ml Bottle 85.41USD bottle Cortisporin 3.5-10000-1 Solution 10ml Bottle 84.33USD bottle Proctofoam HC 1-1% Foam 10 gm Can 81.9USD can Cortisporin 3.5-10000-1 Suspension 10ml Bottle 79.55USD bottle Locoid 0.1% Solution 20ml Bottle 79.28USD bottle Cortisporin 1% Ointment 15 gm Tube 75.09USD tube Locoid 0.1% Cream 15 gm Tube 67.49USD tube Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube 64.75USD tube Locoid 0.1% Ointment 15 gm Tube 62.04USD tube Hydrocortisone Valerate 0.2% Ointment 60 gm Tube 56.74USD tube Hydrocortisone 2.5% Lotion 59 gm Bottle 55.61USD bottle Westcort 0.2% Ointment 60 gm Tube 55.0USD tube Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube 54.37USD tube Westcort 0.2% Ointment 15 gm Tube 50.99USD tube Hydrocortisone Butyrate 0.1% Cream 45 gm Tube 49.43USD tube Hydrocortisone Valerate 0.2% Ointment 45 gm Tube 48.73USD tube Hydrocortisone 2.5% Lotion 59ml Bottle 47.47USD bottle Westcort 0.2% Ointment 45 gm Tube 46.97USD tube Hydrocortisone Valerate 0.2% Cream 60 gm Tube 44.99USD tube Hydrocortisone Valerate 0.2% Cream 45 gm Tube 33.99USD tube Ala Scalp 2% Lotion 29.6ml Bottle 30.99USD bottle Hydrocortisone Valerate 0.2% Ointment 15 gm Tube 30.56USD tube Westcort 0.2% Cream 15 gm Tube 25.99USD tube Hydrocortisone Valerate 0.2% Cream 15 gm Tube 19.99USD tube Cortisporin eye drops 19.74USD ml Solu-Cortef 1 g/vial 17.55USD vial Hydrocortisone 1% Lotion 118ml Bottle 15.99USD bottle Hydrocortisone Acetate 12 25 mg Suppository Box 15.01USD box Hydrocortisone 2.5% Ointment 28.35 gm Tube 13.68USD tube Hydrocortisone 2.5% Cream 30 gm Tube 13.67USD tube Colocort 100 mg/60ml Enema 60ml Bottle 13.15USD bottle Hydrocortisone 100 mg/60ml Enema 60ml Bottle 12.6USD bottle Hydrocortisone 0.5% Cream 28.35 gm Tube 11.99USD tube Hydrocortisone 1% Cream 15 gm Tube 11.99USD tube Hydrocortisone 1% Cream 28 gm Tube 11.99USD tube Hydrocortisone Acetate 1-1% Ointment 30 gm Tube 11.99USD tube Solu-Cortef 500 mg/vial 10.47USD vial Hydrocortisone hemisucc powder 9.9USD g Cortifoam 10% aerosol 9.35USD g Hydrocortisone Sod. Succinate 1 g/vial 9.01USD vial Solu-cortef (pf) 250 mg vial 8.58USD vial Cortisporin-tc ear susp 8.3USD ml Cortisporin ear suspension 7.86USD ml Solu-Cortef 250 mg/vial 7.05USD vial Cortenema (100 mg/60Ml) 100 mg/enm Enema 6.96USD enema Proctofoam-hc foam 6.77USD g Cortifoam 10 % Foam 6.14USD g Hycort (100 mg/60Ml) 100 mg/enm Enema 5.79USD enema Cortamed 2.5 % Ointment 5.67USD g Hydrocortisone Sod. Succinate 500 mg/vial 5.34USD vial Hydrocortisone powder 5.19USD g Solu-cortef (pf) 100 mg vial 4.85USD vial Solu-cortef 100 mg vial 4.63USD vial Proctocort 1% cream 4.37USD g Pandel 0.1% cream 4.34USD g Locoid 0.1% lipocream 4.3USD g Solu-Cortef 100 mg/vial 4.07USD vial Locoid 0.1% cream 3.92USD g Hydrocortisone Sod. Succinate 250 mg/vial 3.56USD vial Hydrocortisone ss 250 mg vial 3.5USD vial Anusol-hc 2.5% cream 3.45USD g Hydrocortisone acet powder 3.15USD g Proctofoam 2.89USD g A-hydrocort 100 mg vial 2.42USD each Proctocream-hc 2.5% cream 2.17USD g Hydrocortisone Sod. Succinate 100 mg/vial 2.1USD vial Hydrocortisone val 0.2% cream 2.07USD g Hytone 2.5% cream 1.46USD g Hydrocortisone buty 0.1% cream 1.31USD g First hydrocort 10% gel 1.18USD g Westcort 0.2% cream 1.17USD g Procto-kit 1% cream 1.08USD g Ala-scalp hp 2% lotion 1.03USD ml Cortef 20 mg tablet 0.9USD tablet Proctosol-hc 2.5% cream 0.89USD g Proctozone-hc 2.5% cream 0.83USD g Orabase plain paste 0.77USD g Hydrocortisone 2.5% lotion 0.6USD ml Cortef 10 mg tablet 0.55USD tablet Orabase-b 20% gel 0.55USD g Hydrocortisone 2.5% cream 0.53USD g Hydrocortisone 10 mg tablet 0.52USD tablet Cortef 5 mg tablet 0.45USD tablet Ala-cort 1% cream 0.43USD g Hydrocortisone 5 mg tablet 0.38USD tablet Corticaine 0.5% cream 0.37USD g Hydrocortisone 20 mg tablet 0.32USD tablet Prevex Hc 1 % Occlusive Cream 0.3USD g Emo-Cort 2.5 % Cream 0.26USD g Preparation h 1% cream 0.24USD g Tucks hydrocortisone ointment 0.24USD g Emo-Cort 2.5 % Lotion 0.23USD g Emo-Cort Scalp 2.5 % Lotion 0.22USD g Colocort 100 mg enema 0.21USD ml Cortenema 100 mg enema 0.21USD ml Sarna Hc 2.5 % Lotion 0.2USD g Emo-Cort 1 % Cream 0.19USD g Balneol lotion 0.18USD ml Emo-Cort 1 % Lotion 0.18USD g Lanacort 1% cool creme 0.18USD g Hyderm 0.5 % Cream 0.18USD g Hytone 1% cream 0.17USD g Cortoderm Mild 0.5 % Ointment 0.15USD g Beta hc 1% lotion 0.14USD ml Cortizone-10 1% spray 0.14USD ml Hydroval 0.2 % Cream 0.13USD g Hydroval 0.2 % Ointment 0.13USD g Aquanil hc 1% lotion 0.12USD ml Hydrocortisone plus 12 1% crm 0.12USD g Scalpicin 3% liquid 0.12USD ml Slender cortisol capsule 0.12USD capsule Cortaid 1% spray 0.1USD ml Sarna Hc 1 % Lotion 0.1USD g Hydrocortisone 0.5% cream 0.08USD g Hydrocortisone 1% cream 0.08USD g Uniderm moisturizer 0.05USD ml Cortoderm Regular 1 % Ointment 0.04USD g Hyderm 1 % Cream 0.04USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5635497 No 1994-06-03 2014-06-03 US US7378405 No 2006-12-19 2026-12-19 US US7981877 No 2005-01-23 2025-01-23 US USRE39264 No 1996-08-02 2016-08-02 US US6514980 No 1999-01-24 2019-01-24 US US7223387 No 2001-07-24 2021-07-24 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 220 °C PhysProp water solubility 320 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 1.61 HANSCH,C ET AL. (1995) logS -2.97 ADME Research, USCD Caco2 permeability -4.66 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.199 mg/mL ALOGPS logP 1.79 ALOGPS logP 1.28 ChemAxon logS -3.3 ALOGPS pKa (Strongest Acidic) 12.58 ChemAxon pKa (Strongest Basic) -2.8 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 94.83 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 97.4 m3·mol-1 ChemAxon Polarizability 39.55 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9918 Blood Brain Barrier + 0.9383 Caco-2 permeable - 0.5096 P-glycoprotein substrate Substrate 0.7861 P-glycoprotein inhibitor I Non-inhibitor 0.7847 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Non-inhibitor 0.7463 CYP450 2C9 substrate Non-substrate 0.8496 CYP450 2D6 substrate Non-substrate 0.9138 CYP450 3A4 substrate Substrate 0.7407 CYP450 1A2 substrate Non-inhibitor 0.9406 CYP450 2C9 inhibitor Non-inhibitor 0.9072 CYP450 2D6 inhibitor Non-inhibitor 0.9418 CYP450 2C19 inhibitor Non-inhibitor 0.9253 CYP450 3A4 inhibitor Non-inhibitor 0.8902 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9095 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.9597 Biodegradation Not ready biodegradable 0.925 Rat acute toxicity 1.8914 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.95 hERG inhibition (predictor II) Non-inhibitor 0.584
Spectra
- Mass Spec (NIST)
- Download (2.96 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols show 4 more
- Substituents
- Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid show 16 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3-oxo steroid, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 21-hydroxy steroid, C21-steroid (CHEBI:17650) / Pregnane and derivatives [Fig], Glucocorticoids, C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C00735) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030001)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
- Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
- Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
- Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
- Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Structural molecule activity
- Specific Function
- Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
- Gene Name
- ANXA1
- Uniprot ID
- P04083
- Uniprot Name
- Annexin A1
- Molecular Weight
- 38713.855 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9. [PubMed:11142771]
- White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73. [PubMed:1712816]
- Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. [PubMed:8060156]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Steroid binding
- Specific Function
- Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation...
- Gene Name
- HSD11B2
- Uniprot ID
- P80365
- Uniprot Name
- Corticosteroid 11-beta-dehydrogenase isozyme 2
- Molecular Weight
- 44126.06 Da
References
- Furstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A: The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61. doi: 10.1093/toxsci/kfs022. Epub 2012 Jan 23. [PubMed:22273746]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Steroid delta-isomerase activity
- Specific Function
- 3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system pl...
- Gene Name
- HSD3B1
- Uniprot ID
- P14060
- Uniprot Name
- 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1
- Molecular Weight
- 42251.25 Da
References
- Bhatia C, Oerum S, Bray J, Kavanagh KL, Shafqat N, Yue W, Oppermann U: Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25. doi: 10.1016/j.cbi.2014.12.013. Epub 2014 Dec 16. [PubMed:25526675]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitorInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid 11-beta-monooxygenase activity
- Specific Function
- Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
- Gene Name
- CYP11B1
- Uniprot ID
- P15538
- Uniprot Name
- Cytochrome P450 11B1, mitochondrial
- Molecular Weight
- 57572.44 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid 11-beta-monooxygenase activity
- Specific Function
- Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
- Gene Name
- CYP11B2
- Uniprot ID
- P19099
- Uniprot Name
- Cytochrome P450 11B2, mitochondrial
- Molecular Weight
- 57559.62 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Androgen binding
- Specific Function
- Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
- Gene Name
- SHBG
- Uniprot ID
- P04278
- Uniprot Name
- Sex hormone-binding globulin
- Molecular Weight
- 43778.755 Da
References
- Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR: Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab. 2006 Nov;91(11):4313-8. Epub 2006 Aug 15. [PubMed:16912126]
- Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL: Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. Psychoneuroendocrinology. 2007 Feb;32(2):140-50. Epub 2007 Jan 31. [PubMed:17270355]
- Lombardi G, Mondaini N, Macchiarella A, Del Popolo G: Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007 Sep-Oct;28(5):722-6. Epub 2007 May 9. [PubMed:17494102]
- Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA: A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 Nov-Dec;14(6):985-94. [PubMed:17507833]
- Rizzo L, Dobrovsky V, Danilowicz K, Kral M, Cross G, Serra HA, Bruno OD: Low-dose glucocorticoids in hyperandrogenism. Medicina (B Aires). 2007;67(3):247-52. [PubMed:17628912]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Steroid binding
- Specific Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Henley DE, Lightman SL: New insights into corticosteroid-binding globulin and glucocorticoid delivery. Neuroscience. 2011 Apr 28;180:1-8. doi: 10.1016/j.neuroscience.2011.02.053. Epub 2011 Mar 1. [PubMed:21371536]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
- Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]
- Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
- Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010]
- Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22. [PubMed:8713080]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893]
- Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:00